Galera Therapeutics Enters Material Definitive Agreement
Ticker: GRTX · Form: 8-K · Filed: Oct 27, 2025 · CIK: 1563577
Sentiment: neutral
Topics: material-definitive-agreement, filing
TL;DR
Galera Therapeutics signed a big deal on 10/21. Details TBD.
AI Summary
On October 21, 2025, Galera Therapeutics, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices in Malvern, PA, filed this 8-K report on October 27, 2025. Specific details of the agreement are not provided in this excerpt.
Why It Matters
This filing indicates a significant new contract or partnership for Galera Therapeutics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The filing reports a material definitive agreement, which is significant but lacks specific details, making the immediate risk level moderate.
Key Numbers
- 001-39114 — SEC File Number (Identifies the company's filing history with the SEC.)
- 46-1454898 — EIN (Employer Identification Number for tax purposes.)
Key Players & Entities
- Galera Therapeutics, Inc. (company) — Registrant
- October 21, 2025 (date) — Date of earliest event reported
- October 27, 2025 (date) — Date of report
- Malvern, PA (location) — Principal executive offices
- Delaware (location) — State of incorporation
FAQ
What type of material definitive agreement did Galera Therapeutics enter into?
The filing states that Galera Therapeutics, Inc. entered into a material definitive agreement on October 21, 2025, but does not specify the nature of the agreement.
When was this 8-K report filed?
This Form 8-K report was filed on October 27, 2025.
What is Galera Therapeutics, Inc.'s principal executive office address?
The principal executive offices of Galera Therapeutics, Inc. are located at 101 Lindenwood Drive, Suite 225, Malvern, PA 19355.
In which state was Galera Therapeutics, Inc. incorporated?
Galera Therapeutics, Inc. was incorporated in Delaware.
What is the SIC code for Galera Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Galera Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 655 words · 3 min read · ~2 pages · Grade level 11.1 · Accepted 2025-10-27 07:30:07
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share GRTX OTCQB Mark
Filing Documents
- d904873d8k.htm (8-K) — 25KB
- d904873dex101.htm (EX-10.1) — 11KB
- g904873dsp1.jpg (GRAPHIC) — 11KB
- 0001193125-25-250698.txt ( ) — 171KB
- grtx-20251021.xsd (EX-101.SCH) — 3KB
- grtx-20251021_lab.xml (EX-101.LAB) — 18KB
- grtx-20251021_pre.xml (EX-101.PRE) — 11KB
- d904873d8k_htm.xml (XML) — 4KB
01 - Financial Statements and Exhibits
Item 9.01 - Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Notice of Assignment to Blackstone Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GALERA THERAPEUTICS, INC. Date: October 27, 2025 By: /s/ J. Mel Sorensen, M.D. J. Mel Sorensen, M.D. President and Chief Executive Officer